133 related articles for article (PubMed ID: 9089558)
1. Comparison of the local tolerability and adhesion of a new matrix system (Menorest) for estradiol delivery with an established transdermal membrane system (Estraderm TTS).
Erianne JA; Winter L
Maturitas; 1997 Mar; 26(2):95-101. PubMed ID: 9089558
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of Menorest 50 compared with Estraderm TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter, parallel group study.
Pornel B; Genazzani AR; Costes D; Dain MP; Lelann L; Vandepol C
Maturitas; 1995 Nov; 22(3):207-18. PubMed ID: 8746878
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). I. Tolerability, adhesion and efficacy.
Rozenbaum H; Birkhäuser M; De Nooyer C; Lambotte R; Pornel B; Schneider H; Studd J
Maturitas; 1996 Nov; 25(3):161-73. PubMed ID: 8981333
[TBL] [Abstract][Full Text] [Related]
4. Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). II. Local skin tolerability.
Rozenbaum H; Birkhäuser M; De Nooyer C; Lambotte R; Pornel B; Schneider H; Studd J; Thebault J
Maturitas; 1996 Nov; 25(3):175-85. PubMed ID: 8981334
[TBL] [Abstract][Full Text] [Related]
5. 17Beta-estradiol delivered by three different matrix patches 50 microg/day: a three way cross-over study in 21 postmenopausal women.
Rohr UD; Nauert C; Stehle B
Maturitas; 1999 Sep; 33(1):45-58. PubMed ID: 10585173
[TBL] [Abstract][Full Text] [Related]
6. Bioavailability of estradiol from two matrix transdermal delivery systems: Menorest and Climara.
Andersson TL; Stehle B; Davidsson B; Höglund P
Maturitas; 2000 Jan; 34(1):57-64. PubMed ID: 10687883
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of Menorest in two positive-controlled studies.
Pornel B
Eur J Obstet Gynecol Reprod Biol; 1996 Apr; 64 Suppl():S35-7. PubMed ID: 8732472
[TBL] [Abstract][Full Text] [Related]
8. New trends in transdermal technologies: development of the skin patch, Menorest.
Marty JP
Int J Gynaecol Obstet; 1996 Mar; 52 Suppl 1():S17-20. PubMed ID: 8666122
[TBL] [Abstract][Full Text] [Related]
9. Comparative bioequivalence studies with Estradot and Menorest transdermal systems.
Hossain M; Quebe-Fehling E; Sergejew T; Schmidt G; Skerjanec A; Cohen A; Krinsky L; Ibarra de Palacios P
Maturitas; 2003 Nov; 46(3):187-98. PubMed ID: 14585521
[TBL] [Abstract][Full Text] [Related]
10. OESCLIM: an advanced delivery system for HRT.
Munoz A
Maturitas; 1999 Nov; 33 Suppl 1():S39-47. PubMed ID: 10661614
[TBL] [Abstract][Full Text] [Related]
11. Bioavailability Study of Menorest®, a New Estrogen Transdermal Delivery System, Compared with a Transdermal Reservoir System.
Le Roux Y; Borg ML; Sibille M; Thebault J; Renoux A; Douin MJ; Djebbar F; Dain MP
Clin Drug Investig; 1995 Sep; 10(3):172-8. PubMed ID: 27519201
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of Estraderm MX, a new estradiol matrix patch.
Bacchi-Modena A; Bolis P; Campagnoli C; De Cicco F; Meschia M; Pansini F; Pisati R; Hüls G
Maturitas; 1997 Jul; 27(3):285-92. PubMed ID: 9288701
[TBL] [Abstract][Full Text] [Related]
13. Menorest: a clinical overview.
Wren B
Int J Gynaecol Obstet; 1996 Mar; 52 Suppl 1():S27-9. PubMed ID: 8666124
[TBL] [Abstract][Full Text] [Related]
14. Menorest: technical development and pharmacokinetic profile.
Marty JP
Eur J Obstet Gynecol Reprod Biol; 1996 Apr; 64 Suppl():S29-33. PubMed ID: 8732471
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of irritation and sensitisation of two 50 microg/day oestrogen patches.
Toole J; Silagy S; Maric A; Fath B; Quebe-Fehling E; Ibarra de Palacios P; Laurin L; Giguere M
Maturitas; 2002 Dec; 43(4):257-63. PubMed ID: 12468134
[TBL] [Abstract][Full Text] [Related]
16. Comparison of pharmacokinetic profiles of a 17 beta-estradiol gel 0.6 mg/g (Gelestra) with a transdermal delivery system (Estraderm TTS 50) in postmenopausal women at steady state.
Paoletti AM; Pilia I; Nannipieri F; Bigini C; Melis GB
Maturitas; 2001 Dec; 40(3):203-9. PubMed ID: 11731181
[TBL] [Abstract][Full Text] [Related]
17. Comparative study to evaluate skin irritation and adhesion of Estradot and Climara in healthy postmenopausal women.
Ibarra de Palacios P; Schmidt G; Sergejew T; Quebe-Fehling E; Lockhart L; Krinsky L
Climacteric; 2002 Dec; 5(4):383-9. PubMed ID: 12626218
[TBL] [Abstract][Full Text] [Related]
18. Estradiol pharmacokinetics after transdermal application of patches to postmenopausal women: matrix versus reservoir patches.
Reginster JY; Donazzolo Y; Brion N; Lins R
Climacteric; 2000 Sep; 3(3):168-75. PubMed ID: 11910618
[TBL] [Abstract][Full Text] [Related]
19. The effect of site of application on the transcutaneous absorption of 17-beta estradiol from a transdermal delivery system (Climara).
Taggart W; Dandekar K; Ellman H; Notelovitz M
Menopause; 2000; 7(5):364-9. PubMed ID: 10993035
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of a new estradiol delivering matrix patch (Estraderm MX) in postmenopausal women.
de Vrijer B; Snijders MP; Troostwijk AL; Thé S; Iding RJ; Friese S; Smit DA; Schierbeek JM; Brandts H; van Kempen PJ; van Buuren I; Monza G
Maturitas; 2000 Jan; 34(1):47-55. PubMed ID: 10687882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
